|
Lower Fas-associated phosphatase-1 expression predicted poor outcome in acute myeloid leukemia patients
Nahla F.A. Osman MSc, MD, MRCP and MRCPath 1, Walaa M.H. Alzobary2, Mohamed A.M. Samra3, Hala H Alsaid4, Iman A Eltounsi5
1 Haematology Unit, Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Clinical Pathology, Shebin El Kom Teaching Hospital, Shebin El Kom, Egypt
3 Department of Haemato-Oncology, National Cancer Institute, Cairo, Egypt
4 Department of Biochemistry, National Liver Institute, Menoufia University, Menoufia, Egypt
5 Department of Clinical Pathology, Menoufia University, Menoufia, Egypt
Correspondence Address:
Nahla F.A. Osman
Haematology Unit, Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Shebin El Kom
Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1110-1067.196175
|
|
Background Fas-associated phosphatase-1 (FAP-1) mediates tumor suppressor and tumor promoter effects through the inhibition of oncogenic tyrosine kinases and apoptosis, respectively. It was claimed responsible for the pathogenesis of some cancers; nevertheless, its role in acute myeloid leukemia (AML) is not clear.
Patients and Methods FAP-1 expression was measured in 20 new AML patients and 12 apparently healthy individuals using real-time PCR.
Results FAP-1 expression was significantly lower in AML patients compared with controls (P<0.001). Patients with relatively higher FAP-1 expression had significantly higher hemoglobin and platelets but lower white cell count (WCC) and lactic dehydrogenase (LDH) (P<0.001), thus reflecting lower tumor burden in this group. Patients’ response was assessed on day 28 after chemotherapy; we found that one of seven patients with FAP-1 expression up to 0.03945 achieved complete remission (CR) compared with eight of 13 patients with levels more than 0.03945. FAP-1 levels predicted the response in the subgroup with normal karyotype and in those with no FLT3-ITD as the majority of those with higher levels achieved CR (77.8 and 80%, respectively), whereas CR was seldom achieved in those with low levels.
Conclusion Our data showed significantly reduced FAP-1 expression in AML patients. FAP-1 can be a useful tool in identifying patient’s risk in AML as the level of expression predicted the response.
|
